Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03818243
Other study ID # CHU-421
Secondary ID 2018-A02417-48
Status Completed
Phase N/A
First received
Last updated
Start date January 21, 2019
Est. completion date June 22, 2023

Study information

Verified date July 2023
Source University Hospital, Clermont-Ferrand
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Investigator have recently shown that Parkinson disease patients' with restless leg Syndrome have more frequent impulse control behavior in particular compulsive feeding that patients without Restless Leg Syndrome (RLS). Investigator hypothesized that presence of RLS in parkinsonian patients could be a risk factor for the emergence of TCI or associated behaviors, occurring preferentially at night. The main objective of this study is to evaluate in patients with idiopathic Parkinson's disease (IPD) the effect of the presence of a RLS on the evening compulsive eating behavior by studying the circadian modulation of food intake of patients with RLS and impulse control disorders. For this investigator conduct a prospective study, with 2 groups of Parkinson disease patients (with and without restless leg syndrome), to which investigator have to fill an agenda to know the schedule of the behaviors during the day and the night.


Description:

Type of study: prospective, case control study Number of center: 1 (Clermont Ferrand) Patients: The study will be performed in 60 patients with Parkinson disease (30 with RLS and 30 without RLS) Study Performance: During the first visit (baseline, inclusion visit, 1 hour), each patient will perform an interview about medical history and a neurological examination in order to identify RLS (evaluation using the IRLSSG rating scale). - Parkinson disease severity will be assessed with the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS UPDRS) and the Hoehn and Yahr scale. - Cognitive assessment will be evaluated with the Montreal Cognitive assessment (MoCA) - Blood test to explore plasma ferritin, renal function and plasma glucose. A diary to note all the impulse control behaviour will be given to each patient in order to be completed for the next visit. Finally, an actimetry system (a watch) will be also provided for each patient in order to record the sleep-wake rhythm and to evaluate the quality and the duration of the sleep. During the second visit (Baseline + 15 days), each patients will have : - a neuropsychological assessment (using the Ardouin scale of behavior in Parkinson's disease ASBPD) - an evaluation of the night eating disorders : - The night eating syndrome will be evaluated with Night Eating Questionnaire (NEQ) - The Sleep related eating disorders will be evaluated with the International classification of sleep disorders-third edition criteria - an evaluation of the Iimpulse control disorder using the questionnaire for impulsive-compulsive disorders in Parkinson's disease rating scale (QUIP RS). - A sleep and vigilance evaluation using the Epworth scale, the Parkinson's disease sleep scale, the single-question screen for rapid eye movement sleep behavior disorder and the REM sleep behavior disorder screening questionnaire. Diary and actimetry will be recovered.


Recruitment information / eligibility

Status Completed
Enrollment 55
Est. completion date June 22, 2023
Est. primary completion date June 16, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Men or women, 18 to 80 years - Patients with a Parkinson disease (PD) with UKPDSBB criteria - with a medical treatment or other treatment, not modified 4 weeks before inclusion - Social security affiliation - Acceptance of the protocol and signature of a written consent RLS group: Patients with IRLSSG criteria of RLS, with a frequency of RLS = 2 times per week Group without RLS: Patients without IRLSSG criteria of RLS Exclusion Criteria: - Patients with an other neurological disease than Parkinson's disease - Patients with secondary RLS (other than Parkinson's disease) - Patients with psychiatric diseases - Patients with cognitive disorder (MoCA <21) - Patients with body mass index <16.5 or >30 - Patients with sleep-waking rhythm disorders (such as night work…) - Patients under trusteeship or guardianship or safeguarding of justice

Study Design


Intervention

Behavioral:
Diary (for reporting all impulse control disorders especially compulsive eating disorders)
During 7 days, at home, patients must report in their diary all their impulse control disorders especially their compulsive eating disorders. They will detailed each food intake and drink intake and the time.

Locations

Country Name City State
France Chu Clermont-Ferrand Clermont-Ferrand

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Clermont-Ferrand

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary The percentage of daily night food intake measured at baseline + 15 day using the diary. at baseline + 15 day
Secondary Percentage of night behavior for the other impulse control disorders , measured at baseline + 15 day using the diary at baseline + 15 day
Secondary Percentage of patients with compulsive food intake measured at baseline + 15 day at baseline + 15 day
Secondary Percentage of patients with others impulse control disorders or other associated behavior measured at baseline + 15 day at baseline + 15 day
Secondary Percentage of patients with the night eating syndrome using the Night Eating Questionnaire measured at baseline + 15 days at baseline + 15 day
Secondary Percentage of patients with Sleep related eating disorders using the International classification of sleep disorders-third edition criteria measured at baseline + 15 days at baseline + 15 day
Secondary sleep caracteristics measured at baseline + 15 days using the accelerometry data at baseline + 15 day
See also
  Status Clinical Trial Phase
Completed NCT05415774 - Combined Deep Brain Stimulation in Parkinson's Disease N/A
Recruiting NCT04691661 - Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease Phase 2
Active, not recruiting NCT05754086 - A Multidimensional Study on Articulation Deficits in Parkinsons Disease
Completed NCT04045925 - Feasibility Study of the Taïso Practice in Parkinson's Disease N/A
Recruiting NCT04194762 - PARK-FIT. Treadmill vs Cycling in Parkinson´s Disease. Definition of the Most Effective Model in Gait Reeducation N/A
Completed NCT02705755 - TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT05830253 - Free-living Monitoring of Parkinson's Disease Using Smart Objects
Recruiting NCT03272230 - Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System N/A
Recruiting NCT06139965 - Validity and Reliability of the Turkish Version of the Comprehensive Coordination Scale in Parkinson's Patients
Completed NCT04580849 - Telerehabilitation Using a Dance Intervention in People With Parkinson's Disease N/A
Completed NCT03980418 - Evaluation of a Semiconductor Camera for the DaTSCAN™ Exam N/A
Completed NCT04477161 - Effect of Ketone Esters in Parkinson's Disease N/A
Recruiting NCT04788693 - Effects of Gait Rehabilitation With Motor Imagery in People With Parkinson's Disease N/A
Completed NCT04942392 - Digital Dance for People With Parkinson's Disease During the COVID-19 Pandemic N/A
Terminated NCT03446833 - LFP Beta aDBS Feasibility Study N/A
Completed NCT03497884 - Individualized Precise Localization of rTMS on Primary Motor Area N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT04997642 - Parkinson's Disease and Movement Disorders Clinical Database
Completed NCT04117737 - A Pilot Study of Virtual Reality and Antigravity Treadmill for Gait Improvement in Parkinson N/A